Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre T Baron

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Biochemistry|June 5, 2013
Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximabJason A Wilken, Marianela Perez-Torres, Rene Nieves-Alicea, et al.
Cell Cycle (Georgetown, Tex.)|December 21, 2012
Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironmentWei Ma, Jing Ma, Jie Xu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 1, 2005
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancerAndre T Baron, Cecelia H Boardman, Jacqueline M Lafky, et al.
Cancer Research|April 19, 2005
Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozoleJacqueline M Lafky, Andre T Baron, Elsa M Cora, et al.
Future Medicinal Chemistry|March 16, 2012
EGFR/HER-targeted therapeutics in ovarian cancerJason A Wilken, Tayf Badri, Sarah Cross, et al.
Cancer Investigation|May 1, 2013
Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancerIwona Podzielinski, Brook A Saunders, Kimberly D Kimbler, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2003
Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancerAndre T Baron, Elsa M Cora, Jacqueline M Lafky, et al.
The Journal of Urology|September 18, 2007
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort studyAndrew M Harris, Bradley W Warner, John M Wilson, et al.
Diagnostics (Basel, Switzerland)|February 3, 2016
Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung AdenocarcinomaAbby L Cosentino-Boehm, Jacqueline M Lafky, Tammy M Greenwood, et al.
Cancer Treatment and Research|September 19, 2009
Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancerAndre T Baron, Jacqueline M Lafky, Cecelia H Boardman, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Biochemistry|June 5, 2013
Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximabJason A Wilken, Marianela Perez-Torres, Rene Nieves-Alicea, et al.
Cell Cycle (Georgetown, Tex.)|December 21, 2012
Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironmentWei Ma, Jing Ma, Jie Xu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 1, 2005
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancerAndre T Baron, Cecelia H Boardman, Jacqueline M Lafky, et al.
Cancer Research|April 19, 2005
Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozoleJacqueline M Lafky, Andre T Baron, Elsa M Cora, et al.
Future Medicinal Chemistry|March 16, 2012
EGFR/HER-targeted therapeutics in ovarian cancerJason A Wilken, Tayf Badri, Sarah Cross, et al.
Cancer Investigation|May 1, 2013
Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancerIwona Podzielinski, Brook A Saunders, Kimberly D Kimbler, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2003
Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancerAndre T Baron, Elsa M Cora, Jacqueline M Lafky, et al.
The Journal of Urology|September 18, 2007
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort studyAndrew M Harris, Bradley W Warner, John M Wilson, et al.
Diagnostics (Basel, Switzerland)|February 3, 2016
Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung AdenocarcinomaAbby L Cosentino-Boehm, Jacqueline M Lafky, Tammy M Greenwood, et al.
Cancer Treatment and Research|September 19, 2009
Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancerAndre T Baron, Jacqueline M Lafky, Cecelia H Boardman, et al.
Pageof 3